Location of Repository

Potential directions for drug development for osteoarthritis

By Helmtrud I. Roach

Abstract

Background: osteoarthritis (OA) is a frustrating disease for both patient and physician because neither cause nor cure is known and there are currently no disease-modifying drugs. Objective: To review current therapeutic approaches as well as new findings regarding OA pathoetiology that could form the basis of future direction for the development of drugs to prevent or slow down disease progression. Methods: After reviewing disease progression in human OA, as demonstrated by histological analyses, the reasons for cartilage erosion are explored and possible therapeutic approaches are highlighted. Results/conclusions: OA may be an epigenetic disease. This new concept can explain many aspects of the disease and provide reasons why therapeutic approaches until now have met with little success

Topics: R1, RZ
Year: 2008
OAI identifier: oai:eprints.soton.ac.uk:72830
Provided by: e-Prints Soton

Suggested articles

Preview

Citations

  1. Activation of interleukin-1 signaling cascades in normal and osteoarthritic articular cartilage. doi
  2. ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. doi
  3. Adenoviral gene transfer into osteoarthritis synovial cells using the endogenous inhibitor IkappaBalpha reveals that most, but not all, inflammatory and destructive mediators are NFkappaB dependent. Rheumatology doi
  4. Adenoviral gene transfer of interleukin-1 in combination with oncostatin M induces significant joint damage in a murine model. doi
  5. Aggrecan degradation in human articular cartilage explants is mediated by both doi
  6. Aggrecan protects cartilage collagen from proteolytic cleavage. doi
  7. (1998). Aggrecan turnover in human articular cartilage: use of aspartic acid racemization as a marker of molecular age. doi
  8. Aggrecanase-mediated cartilage degradation. doi
  9. and
  10. and autoimmune disease. Clin Immunol 2003;109:72-9 doi
  11. Anticytokine therapy for osteoarthritis. doi
  12. AP. doi
  13. Association between the abnormal expression of matrix-degrading enzymes by human osteoarthritic chondrocytes and demethylation of specific CpG sites in the promoter regions. doi
  14. Attwood doi
  15. Ayyanathan K, Lechner MS, Bell P, et al. Regulated recruitment of HP1 to a euchromatic gene induces doi
  16. Biochemical and metabolic abnormalities in articular cartilage from osteo-arthritic human hips. II. Correlation of morphology with biochemical and metabolic data. doi
  17. C, doi
  18. Carvin CD, Parr RD, doi
  19. CCAAT/enhancer-binding proteins beta and delta mediate the repression of gene transcription of cartilage-derived retinoic acid-sensitive protein induced by interleukin-1 beta. doi
  20. Characterization of and osteoarthritis susceptibility in ADAMTS-4-knockout mice. doi
  21. (2003). Collagens – major component of the physiological cartilage matrix, major target of cartilage degeneration, major tool in cartilage repair. Adv Drug Deliv Rev doi
  22. Cytokines as therapeutic targets for osteoarthritis. doi
  23. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. doi
  24. (2007). Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patient. Rheum Dis Clin North Am doi
  25. Disease-modifying therapies for osteoarthritis: current status. doi
  26. Eckhardt F, Lewin J, Cortese doi
  27. Effect of collagen turnover on the accumulation of advanced glycation end products. doi
  28. Effect of inhibition of matrix metalloproteinases on cartilage loss in vitro and in a guinea pig model of osteoarthritis. doi
  29. Egr-1 mediates transcriptional repression of COL2A1 promoter activity by interleukin-1beta.
  30. (2006). Epigenetic mechanisms contribute to pluripotency and cell lineage determination of embryonic stem cells. Stem Cells doi
  31. (2007). ESE-1 is a potent repressor of type II collagen gene (COL2A1) transcription in human chondrocytes. doi
  32. essentials of DNA methylation. Cell 1992;70:5-8 doi
  33. Extracellular superoxide dismutase and oxidant damage in osteoarthritis. doi
  34. Fujita N, Watanabe S, Ichimura T, et al. Methyl-CpG binding domain doi
  35. Fuks F, Hurd PJ, Wolf
  36. genetics revisited: relevance of epigenetics. Trends Genet 2001;17:142-6 doi
  37. Goldring MB. The role of cytokines in cartilage matrix degeneration in osteoarthritis. doi
  38. Gouze JN, Gouze E, Popp MP, et al. Exogenous
  39. Hother C, Jones PA. Epigenetic doi
  40. Hylan versus hyaluronic acid for osteoarthritis of the knee: a systematic review and meta-analysis. doi
  41. IL-1 induces collagenase-3 (MMP-13) promoter activity in stably transfected chondrocytic cells: requirement for Runx-2 and activation by p38 MAPK and JNK pathways. doi
  42. IL-1beta induction of IL-6 and LIF in normal articular human chondrocytes involves the ERK, p38 and NFkappaB signaling pathways. doi
  43. Iliopoulos D, Malizos KN, Tsezou A. Epigenetic regulation of leptin doi
  44. (1999). Immunohistological analysis of cytokine expression in human osteoarthritic and healthy cartilage.
  45. Interleukin-1 in combination with oncostatin M up-regulates multiple genes in chondrocytes: implications for cartilage destruction and repair. doi
  46. J, doi
  47. King doi
  48. Kirillov A, Kistler B, Mostoslavsky R, et doi
  49. Loughlin J. doi
  50. M, doi
  51. Martin doi
  52. Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage: associations with degenerative changes. doi
  53. (2003). Metalloproteinases: their role in arthritis and potential as therapeutic targets. Expert Opin Ther Targets doi
  54. Molecular targets in osteoarthritis: metalloproteinases and their inhibitors. doi
  55. Mund C, Brueckner B, Lyko F. Reactivation doi
  56. Nan X, Ng HH, Johnson CA, et
  57. Nitric oxide and inflammatory mediators in the perpetuation of osteoarthritis. doi
  58. Nitric oxide synthases and osteoarthritis. doi
  59. Osteoarthritis and osteoporosis: clinical and research evidence of inverse relationship. doi
  60. Osteoarthritis cartilage histopathology: grading and staging. doi
  61. (2005). Osteoarthritis: an overview of the disease and its treatment strategies. Semin Arthritis Rheum doi
  62. (2006). Osteoarthritis: pathobiology-targets and ways for therapeutic intervention. Adv Drug Deliv Rev doi
  63. Phenotypic doi
  64. (2007). Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival. doi
  65. Poschl E, Fidler A, Schmidt B, et al. DNA methylation is not likely to be doi
  66. Prostaglandin E2 receptors EP1 and EP4 are up-regulated in rabbit chondrocytes by IL-1beta, but not by TNFalpha. doi
  67. Protein kinases in chondrocyte signaling and osteoarthritis. doi
  68. (2007). Reactive nitrogen and oxygen species in interleukin-1-mediated DNA damage associated with osteoarthritis. Osteoarthritis Cartilage doi
  69. (1997). Ro 32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo. doi
  70. Role of interleukin-1 and tumor necrosis factor alpha in matrix degradation of human osteoarthritic cartilage. doi
  71. S, doi
  72. Scientific basis for the efficacy of combined use of antirheumatic drugs against bone destruction in rheumatoid arthritis. doi
  73. Sekigawa I, Kawasaki doi
  74. Sharma D, Blum J, Yang X, et al. Release of methyl CpG binding proteins and histone deacetylase 1 from the doi
  75. Signaling transduction: target in osteoarthritis. doi
  76. (2002). Sites of collagenase cleavage and denaturation of type II collagen in aging and osteoarthritic articular cartilage and their relationship to the distribution of matrix metalloproteinase 1 and matrix metalloproteinase 13. Arthritis Rheum doi
  77. Small molecular weight inhibitors of stress-activated and mitogen-activated protein kinases. doi
  78. Sp3 represses the Sp1-mediated transactivation of the human COL2A1 gene in primary and de-differentiated chondrocytes. doi
  79. Spector doi
  80. Stability and flexibility of epigenetic gene regulation in mammalian development. doi
  81. Stearns V, Zhou doi
  82. Subchondral bone in osteoarthritis: a biologic link with articular cartilage leading to abnormal remodeling. doi
  83. (2005). Synovial tissue inflammation in early and late osteoarthritis. Ann Rheum Dis
  84. The modulation of matrix metalloproteinase and ADAM gene expression in human chondrocytes by interleukin-1 and oncostatin M: a time-course study using real-time quantitative reverse transcription-polymerase chain reaction. doi
  85. (2007). The pathogenesis of osteoarthritis. doi
  86. (2003). The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis. Rheumatology (Oxford) doi
  87. (2007). The quest for the Holy Grail: a disease-modifying osteoarthritis drug. Arthritis Res Ther doi
  88. The regulation of chondrocyte function by proinflammatory mediators: prostaglandins and nitric oxide. doi
  89. The role of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) in a model of cartilage degradation. doi
  90. The role of cytokines in osteoarthritis pathophysiology. doi
  91. The role of nitric oxide in osteoarthritis. doi
  92. The role of reactive oxygen species in homeostasis and degradation of cartilage. doi
  93. The role of structural genes in the pathogenesis of osteoarthritic disorders.
  94. (2006). Understanding the role of tissue degrading enzymes and their inhibitors in development and disease. Best Pract Res Clin Rheumatol doi
  95. Up-regulation of microsomal prostaglandin E synthase 1 in osteoarthritic human cartilage: critical roles of the ERK-1/2 and p38 signaling pathways. doi
  96. Update on the biology of the chondrocyte and new approaches to treating cartilage diseases. doi
  97. Verschure PJ, Visser AE, Rots MG. Step out of the groove: epigenetic gene control doi
  98. Viscosupplementation with hyaluronans for osteoarthritis of the knee: clinical efficacy and economic implications. doi
  99. Waddell DD, Kolomytkin OV, Dunn S, Marino
  100. Wade PA, Gegonne A, Jones PL,

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.